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http://dx.doi.org/10.1016/j.ccr.2013.04.018SUMMARYParagangliomas are neuroendocrine tumors frequently associatedwithmutations inRET,NF1, VHL, and suc-
cinate dehydrogenase (SDHx) genes. Methylome analysis of a large paraganglioma cohort identified three
stable clusters, associated with distinct clinical features and mutational status. SDHx-related tumors
displayed a hypermethylator phenotype, associated with downregulation of key genes involved in neuroen-
docrine differentiation. Succinate accumulation in SDH-deficient mouse chromaffin cells led to DNA hyper-
methylation by inhibition of 2-OG-dependent histone and DNA demethylases and established a migratory
phenotype reversed by decitabine treatment. Epigenetic silencing was particularly severe in SDHB-mutated
tumors, potentially explaining their malignancy. Finally, inactivating FHmutations were identified in the only
hypermethylated tumor without SDHxmutations. These findings emphasize the interplay between the Krebs
cycle, epigenomic changes, and cancer.INTRODUCTION
Paragangliomas (PGL) are neural crest-derived tumors that arise
from parasympathetic ganglia of the head and neck region orSignificance
Unexpected links between epigenetic and genetic alteration
mutations impair DNA demethylation in gliomas. Mutations affe
acid cycle enzyme, have been identified in several cancers
genome-wide analysis of DNAmethylation changes in a large p
ularly SDHB-relatedmetastatic tumors, display a hypermethyla
implicated in chromaffin cell differentiation. These findings ex
siveness of SDHB-mutated tumors and raise the possibility of i
agents for these cancers.from sympathetic ganglia located in the thorax, abdomen, or
pelvis. These tumors may develop in the adrenal medulla, in
which case they are called pheochromocytomas (PCC) (Lenders
et al., 2005). There has been extensive genetic characterizations were recently identified with the demonstration that IDH
cting succinate dehydrogenase (SDH), another tricarboxylic
and are particularly frequent in paragangliomas. With this
araganglioma cohort, we demonstrate thatSDHx, and partic-
tor phenotype, associatedwith downregulation of key genes
plain the oncogenic effect of SDH inactivation and the inva-
nnovative epigenetic therapies involving DNA demethylating
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Hypermethylator Phenotype in SDH-Related PGL/PCCof PGL/PCC. At least 30%of patients harbor a germlinemutation
in one of the ten identified susceptibility genes (Gimenez-Roque-
plo et al., 2012): RET, NF1, VHL, SDHAF2, TMEM127, or MAX,
and in genes encoding the four subunits of succinate dehydroge-
nase (SDHA, SDHB, SDHC, or SDHD, referred to as SDHx
genes). Integrated genomic analysis of the largest available
cohort of PGL/PCC, recruited by the French COMETE network,
identified homogeneous molecular subgroups associated with
susceptibility genes (Burnichon et al., 2011) and showed that a
large proportion of sporadic PGL/PCC carry a somatic mutation
in VHL, RET, NF1,MAX, or HIF2A genes (Burnichon et al., 2011,
2012a, 2012b; Favier et al., 2012). Overall, 60%of cases harbor a
somatic or germline mutation in a known predisposing gene.
Various important issues remain to be unraveled, including the
oncogenic role of SDHx mutations. Succinate dehydrogenase
was the first mitochondrial enzyme to be identified as a tumor
suppressor in familial PGL (Baysal et al., 2000). Its inactivation
also predisposes to renal cell carcinoma (Ricketts et al., 2008)
and gastrointestinal stromal tumors (Janeway et al., 2011). To
date, the only mechanism linking SDH to cancer involves
hypoxia-inducible factors (HIFs) (Dahia et al., 2005; Gimenez-
Roqueplo et al., 2001). SDH dysfunction results in the accumula-
tion of succinate (Pollard et al., 2005), its tricarboxylic acid cycle
(TCA) substrate, which acts as a competitive inhibitor of the
2-oxoglutarate (2-OG)-dependent HIF prolyl-hydroxylases (Bri-
e`re et al., 2005; Selak et al., 2005). This stabilizes HIF-alpha
and activates genes that facilitate angiogenesis and anaerobic
metabolism. However, the exact role of HIFs in oncogenesis
remains unclear (Young and Simon, 2012). Understanding
SDH-related tumorigenesis is crucial, because the presence of
a germline mutation in the SDHB gene is a major risk factor of
malignancy and of poor prognosis. Around 40% of all patients
with a metastatic form of the disease harbor an SDHB mutation
(Pasini and Stratakis, 2009). SDHB-mutation carriers have a
19-fold higher risk of developing a metastatic disease (Gime-
nez-Roqueplo et al., 2003) and shorter survival than patients
with a malignant PGL/PCC but without SDHB mutations (Amar
et al., 2007).
DNA methylation changes are hallmarks of human cancers
(Hanahan and Weinberg, 2011). Cancer cells often display over-
all DNA hypomethylation and hypermethylation of promoter CpG
islands, resulting in the transcriptional silencing of tumor sup-
pressor genes (Jones and Baylin, 2007). Unlike genetic muta-
tions, DNA methylation is a reversible process and is thus a
promising target for drug development (Rodrı´guez-Paredes
and Esteller, 2011). These epigenetic features are also useful
as biomarkers for early detection of cancer in blood samples,
for prognosis, or for prediction of response to treatment (Laird,
2003). Genome-scale DNA methylation profiling has allowed
the identification of epigenetic subtypes in several cancers
(Hinoue et al., 2012; Noushmehr et al., 2010). A CpG islandmeth-
ylator phenotype (CIMP), characterized by the concerted hyper-
methylation of a large number of genes, was initially described in
colorectal cancer (Toyota et al., 1999) andwas recently identified
in glioma (G-CIMP; Noushmehr et al., 2010). In glioma, the
G-CIMP phenotype is associated with gain-of-function muta-
tions in IDH1 and IDH2 that confer to these enzymes a neomor-
phic capacity to convert a-ketoglutarate (a-KG, or 2-OG) into
the oncometabolite 2-hydroxyglutarate (2-HG). 2-HG acts as a740 Cancer Cell 23, 739–752, June 10, 2013 ª2013 Elsevier Inc.competitive inhibitor of 2-OG-dependent dioxygenases, includ-
ing histone demethylases and the TET family of 5-methyl-
cytosine (5-mC) hydroxylases, leading to genome-wide DNA
methylation alterations (Xu et al., 2011). Succinate also can
inhibit these enzymes in vitro, suggesting that SDH-related
tumorigenesis may involve epigenetic alterations (Xiao et al.,
2012). However, DNAmethylation changes of only a limited num-
ber of genes have been investigated so far in PGL/PCC (Geli
et al., 2008) and have not been compared with expression data
or mutational status.
Here, we report the genome-scale methylome and transcrip-
tome profiling of the well-annotated COMETE cohort and inves-
tigate the relationship betweenSDHxmutations andDNAmethyl-
ation changes in a mouse model of SDH-related paraganglioma.
RESULTS
DNA Methylation-Based Classification of
Pheochromocytomas and Paragangliomas
We determined DNAmethylation profiles of 145 pheochromocy-
tomas and paragangliomas using the Illumina Infinium HM27
DNA methylation assay, which assesses the degree of methyl-
ation of 27,578 CpG sites in promoter regions of 14,495 pro-
tein-coding genes (Bibikova et al., 2009). Gene expression was
previously characterized in most of these samples (Burnichon
et al., 2011), and the mutation status of the main genes predis-
posing to PGL/PCC (SDHx, VHL, NF1, RET, TMEM127, and
MAX) was analyzed (Table S1 available online). As previously
described (Hinoue et al., 2012), we excluded probes that might
be unreliable and probes designed for sequences on sex chro-
mosomes. We selected the 10%most variant probes, according
to the standard deviation of the beta values, and performed
consensus clustering (Monti et al., 2003) to identify DNA methyl-
ation clusters. The optimal classification defined three tumor
subgroups (Figure 1A; Figure S1). Tumors of the M1 cluster dis-
played concerted hypermethylation at a large number of loci
(Figure 1B), reminiscent of the CpG island methylator pheno-
types described in colorectal cancer and glioblastoma.
For comparison, we applied a second clustering approach,
the recursively partitioned mixture model (RPMM; Houseman
et al., 2008), to our data set. Cluster assignments using
consensus clustering and RPMM were strongly correlated (p =
9.73 1039), with the twomethods agreeing on cluster member-
ship for 90% (130/145) of the tumors (Figure S1F). In particular,
the M1 cluster was similarly identified by the RPMM approach,
with only 1/17 samples misclassified. We based our subsequent
analyses on the consensus clusters, which showed better asso-
ciation with clinical criteria.
We next sought to characterize DNA methylation changes in
each cluster. We analyzed probes located within and outside
CpG islands separately (Takai and Jones, 2002). Most CpGs
within CpG islands are demethylated in normal tissues and
undergo hypermethylation in tumors (Jones and Baylin, 2007),
whereas CpGs outside CpG islands are mostly highly methyl-
ated in normal tissues and undergo loss of DNA methylation in
cancers (Feinberg and Vogelstein, 1983). Because of the diffi-
culty in obtaining samples of normal adrenal medulla, only three
normal controls were available, hence the comparison with
tumor clusters had limited power. After FDR adjustment,
A B
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Figure 1. Genome-wide DNA Methylation Profiling of PGL/PCC Identifies a Hypermethylator Phenotype Associated with SDHx Mutations
(A) Unsupervised classification of 145 PGL/PCC samples (see Table S1) identifies three stable DNA methylation clusters. The consensus matrix represents the
similarity between tumors. Consensus index values range from zero (highly dissimilar profiles, white) to one (highly similar profiles, dark blue). Samples are
ordered on the x and y axes by the consensus clustering, which is depicted atop the heatmap. See also Figure S1.
(B) Heatmap representation of DNAmethylation profiles. The degree of DNAmethylation (beta value) for each probe (row) in each sample (column) is represented
with a color scale (dark blue, nonmethylated; yellow, methylated). Tumors are ordered by methylation cluster. Probes are arranged by similarity, as assessed by
hierarchical cluster analysis. The mutation status of the main genes predisposing to PGL/PCC (SDHx, VHL, NF1, and RET) is indicated above the heatmap,
together with expression cluster memberships as determined in a previous study (Burnichon et al., 2011).
(C) Scatterplots comparing methylation levels between tumor subgroups and normal adrenal medulla controls are shown for probes located within (top) or
outside (bottom) CpG islands (Takai-Jones definition [Takai and Jones, 2002]). Probes significantly hyper- or hypomethylated in tumors (p < 0.01) are indicated in
red and green, respectively. See also Table S2.
(D) Kaplan-Meier curves for metastasis-free survival and overall survival.
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Hypermethylator Phenotype in SDH-Related PGL/PCCsignificant methylation differences between tumors and normal
controls were only detected in cluster M1 (1,015 probes with
FDR-adjusted p < 0.05). However, the number of significant tests
(p < 0.01) was substantially higher than expected by chance in
each cluster (8.7%, 4.8%, and 6.4% in M1, M2, and M3, respec-
tively). Cluster M1 tumors displayed a hypermethylator pheno-
type, characterized by high methylation levels at a large number
of CpG sites, both within (7.2% of probes, p < 0.01; Figure 1C;
Table S2) and outside (7.0%) CpG islands. Clusters M2 andM3 did not display substantial hypermethylation within CpG
islands, but a strong hypomethylation outside CpG islands was
observed in both clusters, particularly in cluster M3 (5.9% of
probes hypomethylated in M2, 9.6% in M3).
Association with Genomic and Clinical Features
DNAmethylation clusters were highly associated withmutational
status (p = 3.33 1033) and gene expression clusters (p = 1.33
1041) (Figure 1B; Table 1). In particular, the hypermethylatorCancer Cell 23, 739–752, June 10, 2013 ª2013 Elsevier Inc. 741
Table 1. Clinical and Genomic Characteristics of DNA Methylation Consensus Clusters
Overall (n = 145) Cluster M1 (n = 17) Cluster M2 (n = 14) Cluster M3 (n = 114) p Value
Gender
Female 93 (64%) 11 (65%) 6 (43%) 76 (67%) 0.22
Male 52 (36%) 6 (35%) 8 (57%) 38 (33%)
Age
Median 44 32 25.5 47 1.80 3 107
Range 7–82 10–63 10–49 7–82
Histologya
Paraganglioma 15 (10%) 9 (56%) 1 (7%) 5 (4%) 1.51 3 109
Pheochromocytoma 129 (90%) 7 (44%) 13 (93%) 109 (96%)
Mutational Status
SDHx 17 (12%) 16 (94%) 0 1 (1%) 3.32 3 1033
VHL 21 (14%) 0 13 (93%) 8 (7%)
NF1 30 (21%) 0 0 30 (26%)
RET 13 (9%) 0 0 13 (11%)
Other 64 (44%) 1 (6%) 1 (7%) 62 (54%)
Expression Clustera
C1A 16 (12%) 16 (100%) 0 0 1.33 3 1041
C1B 22 (16%) 0 14 (100%) 8 (8%)
C2A 67 (50%) 0 0 67 (64%)
C2B 22 (16%) 0 0 22 (21%)
C2C 7 (5%) 0 0 7 (7%)
Clinical and genomic features are indicated for each DNA methylation cluster, in absolute numbers and as a percentage of each group size. p values
are obtained by chi-square tests for qualitative variables and ANOVA for age.
aHistology could not be determined for one patient with both abdominal paraganglioma and adrenal pheochromocytoma at first presentation. Gene
expression data were available for 134 samples.
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In cluster M1, 16/17 tumors were SDH-related (1 SDHA,
11 SDHB, 1 SDHC, and 3 SDHD germline mutations), and one
was sporadic. Cluster M2 included 13/21 VHL-related tumors
and one sporadic tumor. All RET and NF1-related samples
were members of cluster M3, together with the remaining spo-
radic and VHL-mutated samples. Clusters M1 and M2 corre-
sponded to the previously described C1A (SDHx-related) and
C1B (VHL-related) expression clusters (Burnichon et al., 2011),
and the M3 cluster comprised all tumors of the C2 (RET/NF1-
related) expression cluster, plus eight tumors from the C1B
group. Age at diagnosis and histology, which are known to be
associated with mutational status (Amar et al., 2005; Neumann
et al., 2002), differed significantly between DNA methylation
clusters (p = 1.8 3 107 and p = 1.5 3 109, respectively). The
median age at diagnosis was younger for clusters M1 (32 years)
andM2 (25.5 years) than for clusterM3 (47 years), and clusterM1
was enriched in paragangliomas (56% versus% 7% in clusters
M2 and M3). Note that only SDH-related paragangliomas dis-
played a hypermethylator phenotype. Hypermethylation is thus
specifically associated with SDHxmutations, rather than a char-
acteristic of extra-adrenal tumors. Methylation clusters were
significantly associated with both metastasis-free survival
(MFS, p = 6.2 3 108) and overall survival (OS, p = 0.0013),
with the prognosis being much worse for M1 tumors than M2
and M3 tumors (Figure 1D). However, the presence of an
SDHB mutation predicted prognosis more significantly than742 Cancer Cell 23, 739–752, June 10, 2013 ª2013 Elsevier Inc.methylation cluster membership in our series (p = 8.9 3 1010
and p = 8.2 3 106 for MFS and OS, respectively).
Sdhb Knockout in Mouse Chromaffin Cells Establishes
a Hypermethylator Phenotype and Promotes Cell
Migration
To investigate the mechanisms linking SDH deficiency with
methylation, we generated an immortalized mouse chromaffin
cell (imCC) line harboring a complete defect in SDH. We created
genetically modified mice in which the endogenous Sdhb exon 2
is flanked by LoxP sites, isolated chromaffin cells from their
adrenal medulla, and deletedSdhb byCre-mediated recombina-
tion (Figure 2A). Suppression of exon 2 leads to a premature stop
codon and to the predicted translation of a truncated 33 amino-
acids protein, instead of the 283 amino-acids wild-type (WT)
SDHB protein. Two independent Sdhb/ clones were studied
(c6 and c8). As previously reported for human tumors (Favier
et al., 2009; van Nederveen et al., 2009), Sdhb-deficient cells
completely lost SDHB protein production but had normal
SDHA levels (Figure S2A). They displayed a selective loss of
SDH/succinate cytochrome c reductase (SCCR) activity (Figures
2B, S2B, and S2C), accompanied by large increases in both
intracellular (Figure 2C) and secreted (Figure S2D) succinate
levels and abnormally small amounts of the following organic
acids (fumarate andmalate) produced by the TCA cycle. Expres-
sion and nuclear translocation of HIF2a were also higher than in
controls (Figures S2E).
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(Meissner et al., 2005) to examine base-pair resolution DNA
methylation patterns in two samples of WT cells and in both
Sdhb/ clones. We obtained more than 15 million high-quality
aligned reads per sample, yielding quantitative DNA methylation
data for 1,530,785 CpG dinucleotides (coverage R 10 reads in
each sample). Hierarchical clustering identified two clusters
corresponding to WT and Sdhb/ cells (Figure 2D). Like
SDHx-related tumors, Sdhb-deficient cells displayed a wide-
spread hypermethylation both within and outside CpG islands
(Figure 2E). We obtained DNA methylation rates with more
than ten individual CpG measurements for 78% of CpG islands
(n = 12,503). CpG islandmethylation rates were highly correlated
between the two WT samples and between the two Sdhb/
clones (Figure S2F). By contrast, 3,357 CpG islands were
significantly hypermethylated, and 242 were significantly hypo-
methylated in Sdhb/ clones as compared to WT cells (FDR-
adjusted p < 0.05 and absolute methylation difference > 5%)
(Figure S2G). Genes hypermethylated in Sdhb-deficient imCCs
significantly overlapped those hypermethylated in SDH-related
PGL/PCC (p = 3.2 3 10170), with 1,014 genes in common (Fig-
ure 2F; Table S3).
Although SDH-deficiency led to a mean 2-fold decrease in
growth rate (Figure S2H), Sdhb/ cells had marked increased
migration capacities as assessed in a wound healing scratch
assay (Figure 2G). These characteristics are consistent with
the known specificities of SDHB-related PGL/PCC, which are
not associated with increased proliferation but are associated
with invasiveness. To investigate the role of DNA methylation in
this phenotype, we treated Sdhb/ cells for 72hr with low
(10 nM) or higher (5 mM) doses of 5-Aza-20-deoxycytidine (deci-
tabine or DAC), an epigenetic modifier that inhibits DNA methyl-
transferase activity. High doses induced cytotoxicity in all cell
types (from 10% to 25% of cell death after 3 days), which was
markedly reduced at low doses (cell death <8%). After drugwith-
drawal, the effect of DAC was assessed on cell proliferation and
migration. We observed a dose-dependant blockade of cell
growth in both WT and Sdhb/ cells (Figure S2H). In contrast,
an inhibition of collective cell migration was specifically
observed in SDH-deficient cells, but not in WT cells (Figure 2H).
SDH-Deficient Chromaffin Cells Display Increased
5-mC/5-hmC Ratio and Histone Methylation
Tet-mediated conversion of 5-mC to 5-hmC was evaluated by
flow cytometry and immunofluorescence analyses: there was
more 5-mC in Sdhb/ than the WT imCCs (Figures 3A and
3B). This effect was reversed by the addition of 2-OG to the cul-
ture medium, which also led to an increase in 5-hmC staining of
Sdhb/ cells (Figure S3A). The methylation of lysines 9 and 27
of histone 3 was then assessed by western blotting. Loss of
Sdhb increased H3K9me3, H3K27me2, and H3K27me3 levels
(Figure 3C, quantified in Figure S3B). As both H3K9 and H3K27
methylation are closely linked with DNA methylation (Cedar
and Bergman, 2009), these effects on histone methylation may
contribute to the establishment of the hypermethylator
phenotype.
To confirm the inhibition of oxidative demethylation by succi-
nate in human PGL/PCC, we first measured succinate and fuma-
rate concentrations in a subset of tumor samples and confirmeda mean 100-fold increase in succinate levels in SDHx- versus
non-SDHx-mutated PGL/PCC (Table S4). We next used immu-
nohistochemistry to quantify 5-mC and 5-hmC, as well as
H3K9me3 and H3K27me3, in 39 paraffin-embedded tumor sam-
ples with various genetic backgrounds. All (16/16) SDHx-
mutated tumors had low 5-hmC levels, whereas 70% (16/23)
of non-SDH samples had high levels of 5-hmC (Figure 3D; Table
S5). Similarly, 81% of SDH-related PGL/PCC displayed abun-
dant H3K27me3, whereas 43% of non-SDH tumors displayed
low H3K27me3 levels (Figure 3E; Table S5). Succinate inhibition
of oxidative demethylation by TET proteins and Jumonji domain-
containing histone demethylases may thus be the mechanism
responsible for the accumulation of DNA methylation in SDH-
deficient tumors.
Transcriptional Changes Associated with
the Hypermethylator Phenotype
To better understand the impact of DNA hypermethylation in
tumors of the M1 cluster, we examined the relationship between
methylation and expression changes in these tumors. Principal
component analysis indicated that the transcriptome differed
between the DNAmethylation subgroups (Figure 4A), consistent
with the strong association between methylation and expression
clusters. Of the 7,136 CpG sites that were differently methylated
in M1 and non-M1 tumors (FDR-adjusted p < 0.05), 6,850 (96%)
were hypermethylated in M1 tumors, resulting in a highly asym-
metric volcano plot (Figure 4B). The transcriptome data, avail-
able for 134/145 samples, revealed a similar asymmetry
(Figure 4C), with 623 genes significantly downregulated (FDR-
adjusted p < 0.05) and 356 genes significantly upregulated in
cluster M1 (Table S6). Integrated transcriptome and methylome
analysis revealed that 11.5% of genes with significant hyperme-
thylation in M1 tumors (FDR-adjusted p < 0.05 and beta value
difference >0.1) also showed more than a 2-fold reduction in
gene expression and that the mean shift in expression values
correlated with the amplitude of the methylation difference (Fig-
ure 4D). To gain a more comprehensive view of DNAmethylation
changes in M1 tumors, we reanalyzed 22 tumors (ten M1, two
M2, and ten M3) using the Illumina Infinium 450K assay, which
assesses the methylation levels of more than 485,000 CpG sites.
Using probes present on both the 27K and 450K arrays, we veri-
fied that the beta value differences between M1 and non-M1
tumors were consistent in the two data sets (mean absolute dif-
ference = 0.023). Overall, we identified 4,663 genes with signifi-
cant hypermethylation of their promoter CpG islands (Table S7).
The overlap between the lists of hypermethylated and downre-
gulated genes was highly significant (p = 1.5 3 107), with 191
genes showing both significant CpG island hypermethylation
and significant downregulation in M1 tumors (Table S8). Gene
ontology analysis of this set of genes showed a significant
enrichment in terms associated with neuroendocrine differentia-
tion (Table S9). Several genes are associated with catechol-
amine metabolic process [PNMT (Figure S4), DRD2, and
SULT1A1], transport (SLC6A2), or secretion (NPY); RET and
NRP2 are implicated in the differentiation of neural-crest cells.
RBP1 is a tumor suppressor known to be epigenetically silenced
in several cancers (Esteller et al., 2002). Downregulation of
SPOCK2, an inhibitor of matrix-metalloproteases, of KRT19 (Fig-
ure S4), a key marker of the epithelial-to-mesenchymal transitionCancer Cell 23, 739–752, June 10, 2013 ª2013 Elsevier Inc. 743
Figure 2. Generation and Characterization of Sdhb-Deficient Mouse Chromaffin Cells
(A) Strategy used for the generation of Sdhb knockout in mouse. The targeting vector comprises mouse Sdhb exon 2 locus flanked with LoxP sites and followed
by a Neomycin (neo) resistance cassette flanked with Frt sites, which is removed after Flip-mediated recombination between the Frt sites. Primers for genotyping
(arrows) are indicated below their target sequences.
(B) SDH activity in WT cells (black) measured by 2,6-dichlorophenol-indophenol reduction (in the presence of rotenone, inhibitor of complex I, and cyanide,
inhibitor of complex IV) is triggered by succinate addition and subsequently inhibited by adding malonate, a specific SDH inhibitor. The subsequent addition of
glycerol-3P triggers the activity of the mitochondrial glycerol-3P dehydrogenase in the same sample. Similar assays were carried out on Sdhb/ c6 (light red)
and c8 (dark red) imCCs. Numbers along the traces are nmol/min per mg protein.
(C) Gas chromatography-mass spectrometry analysis of organic acids revealing a substantial accumulation of succinate and the depletion of fumarate in
Sdhb/ cells relative to controls.
(D) Hierarchical clustering analysis of DNA methylation profiles from four mouse chromaffin cell samples, with (c6 and c8 clones) or without (WT1 and WT2) a
knockout of Sdhb gene, analyzed by reduced representation bisulfite sequencing (RRBS). A heatmap indicates the degree of methylation of the 500 most variant
CpG sites in each sample (dark blue, nonmethylated; yellow, methylated).
(E) Smoothed color density representation of the scatterplots representing DNAmethylation changes betweenWT and Sdhb/ imCCs, within (left) and outside
(right) CpG islands. Only CpG sites showing significantly different methylation rates between WT and Sdhb/ cells are represented.
(F) Comparison of DNAmethylation changes in SDH-related human PGL/PCC and Sdhb/ imCCs. CpG islandmethylation rates were calculated for all mouse/
human gene homologs represented in Illumina methylation arrays and RRBS data. Each point represents a gene, with the CpG island methylation difference
(legend continued on next page)
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Figure 3. Functional Consequences of SDH Inactivation on Oxidative Demethylation
(A) Immunofluorescence showing a larger number of 5-mC-positive nuclei in Sdhb/ clones. Addition of 2-OG to the culture medium reversed this phenotype.
Scale bar = 10 mm.
(B) Fluorescence-activated cell sorting (FACS) analysis also showed that Sdhb knockout leads to an increase in 5-mC in imCCs.
(C) Histone lysine methylation levels were assessed by western blotting with specific antibodies. Total H3 was used as a loading control.
(D) 5-hmC levels were studied on human PGL/PCCwith various genetic backgrounds. Strong immunostaining of endothelial cell nuclei was observed in all tumor
types, whereas the tumor cell staining was weaker in SDHx-mutated tumors. Scale bar = 50 mm.
(E) H3K27me3 levels are shown for tumors with various genetic backgrounds. Scale bar: 100 mm; SPO: sporadic tumor. See also Figure S3 and Tables S4 and S5.
Scale bar = 50 mm.
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Hypermethylator Phenotype in SDH-Related PGL/PCC(EMT) and of DNAJA4, recently shown to be a metastasis sup-
pressor gene (Pencheva et al., 2012), may participate to the inva-
sive phenotype of SDH-deficient cells. These findings indicate
that methylome remodeling results in major transcriptional
abnormalities in SDH-related tumors, directly associated with
their phenotypic characteristics.
ExomeSequencing of theOnly Hypermethylated Sample
without SDHxMutation Identified InactivatingMutations
in the FH Gene
A single tumor in our data set (HS_121) carried noSDHxmutation
but displayed a hypermethylator phenotype (Figure 1B) as well
as both low 5-hmCand high H3K9 andH3K27methylation (Table
S5). This tumor, which also belonged to the C1A (SDH-related)
expression cluster was a local recurrence of an adrenal pheo-betweenSdhb/ andWT imCCs along the y axis and the CpG islandmethylation
Genes significantly hypermethylated in both human tumors and mouse chromaf
(G) Cell migration is shown in a wound scratch assay after 10 hr, in standard med
(H) Reversion of the migratory phenotype by decitabine treatment. Data are mea
See also Figure S2 and Table S3.chromocytoma resected from a 63-year-old female presenting
a high level of urinary normetanephrines. To explain this ‘‘SDH-
like’’ phenotype, we performed the whole-exome sequencing
of tumor and matched blood DNA. We identified 21 nonsynony-
mous somatic mutations effecting exons or splice sites in this
tumor, 16 of which were predicted to have functional conse-
quences (Table S10). In particular, a somatic mutation was iden-
tified in exon 7 of the fumarate hydratase (FH) gene (c.1043G >C,
p.Gly348Ala). This patient also carried a germline mutation in
exon 3 of FH (c.349G > C, p.Ala117Pro). Both mutations were
verified by Sanger sequencing (Figure 5A). The p.Ala117Pro
mutation has been described previously in patients with multiple
leiomyomatosis and/or renal cancer, displaying reduced FH
activity. Interestingly, the patient’s clinical record revealed that
she had benefited from a total hysterectomy at 35 years old fordifference betweenSDHx-related PGL/PCC and other tumors along the x axis.
fin cells are indicated in red.
ium or following 72 hr of DAC treatment at 10 nM or 5 mM. Scale bar = 100 mm.
n ± SEM.
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Figure 4. Transcriptional Changes Associ-
ated with the Hypermethylator Phenotype
in SDH-Related PGL/PCC
(A) Principal component analysis of methylation
(left) and expression (right) profiles of PGL/PCC.
Tumor samples are plotted in three dimensions
using their projections onto the first three principal
components (PC). Methylation cluster member-
ship is represented by a color code as described in
the legend.
(B) Volcano plot analysis of differentially methyl-
ated CpG sites in tumors displaying a hyper-
methylator phenotype (cluster M1). The beta
value difference in DNA methylation between M1
and non-M1 tumors is plotted on the x axis, and
the false-discovery rate (FDR)-adjusted signifi-
cance is plotted on the y axis (log10 scale). Red
indicates probes differing significantly between
groups.
(C) Volcano plot analysis of genes differentially
expressed between M1 and non-M1 tumors.
(D) Integrated analysis of promoter DNA methyl-
ation and gene expression differences between
M1 and non-M1 tumors. The starburst plot (left)
represents the DNA methylation (x axis) and gene
expression (y axis) differences between M1 and
non-M1 tumors. Genes that are hypermethylated
with a beta value difference >0.1 and have a more
than 2-fold decrease in expression levels in M1
tumors are shown as red data points. The pie
chart (top right) shows the proportion of hyper-
methylated genes (FDR adjusted p < 0.05 and
beta value difference >0.1) that are significantly
up- and downregulated in M1 tumors (gene
expression difference >1 and <1, respectively).
The histogram (bottom right) shows the mean
difference in gene expression levels between M1
and non-M1 tumors as a function of the amplitude
of DNA methylation beta value differences. See
also Figure S4 and Tables S6, S7, S8, and S9.
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Hypermethylator Phenotype in SDH-Related PGL/PCChemorrhagic fibromas. The p.Gly348Ala mutation has not been
described previously and was predicted to be ‘‘probably
damaging’’ by Polyphen software. Tumor HS_121 displayed a
selective loss of FH activity (Figure 5B), accompanied by an
increase in fumarate concentrations (Figure 5C). Fumarate, like
succinate, is a competitive inhibitor of 2-OG-dependent dioxy-
genases (Xiao et al., 2012), so these findings strongly suggest
that FH inactivation causes PGL/PCC by establishing a hyper-
methylator phenotype.
DNA Hypermethylation and Associated Gene Silencing
Are Stronger in SDHB-Mutated Tumors
SDHB-mutated PGL/PCC tend to be more malignant than
tumors harboring mutations in other SDH subunits (Amar
et al., 2005; Pasini and Stratakis, 2009). To determine whether
this aggressive behavior is associated with a more severe hy-
permethylator phenotype, we calculated the mean methylation
level across all the CpG sites significantly hypermethylated in746 Cancer Cell 23, 739–752, June 10, 2013 ª2013 Elsevier Inc.M1 tumors and located within CpG
islands. This methylation level was, as
expected, higher in all M1 tumors thanin M2 and M3 tumors (Figure 6A); but, SDHB-mutated tumors
displayed stronger hypermethylation than other M1 tumors
(1 SDHA-, 1 SDHC-, 3 SDHD-, and 1 FH-mutated tumors)
(p = 0.0071). We examined the transcriptional consequences
of these differences by calculating the mean expression level
of the 191 genes significantly hypermethylated and downregu-
lated in M1 tumors (Table S8). Although these genes were
downregulated in all M1 tumors as compared to M2 and M3
tumors, their expression was significantly lower in SDHB-
mutated tumors than in other M1 tumors (p = 0.0055, Fig-
ure 6B). The levels of hypermethylation and downregulation of
target genes were highly correlated (Pearson’s r = 0.93,
p = 7.0 3 1059; Figure 6C), suggesting that DNA methylation
finely regulates the expression of these genes in PGL/PCC.
These findings support the idea that a stronger hypermethylator
phenotype, associated with a stronger downregulation of target
genes, may participate to the metastatic phenotype of SDHB-
mutated tumors.
Figure 5. Inactivating FH Mutations in the Only Hypermethylated
Tumor without SDHx Mutation
(A) Sanger sequencing of FH gene in DNA extracted from peripheral blood and
frozen tumor from patient HS_121 identifies a heterozygous germline mutation
(c.349G > C, p.Ala117Pro) in exon 3 and a heterozygous somatic mutation
(c.1043G > C, p.Gly348Ala) in exon 7.
(B) Enzymatic activity, assayed spectrophotometrically for the forward
(fumarate to malate, left traces) and backward (malate to fumarate, right
traces) directions, reveals a severe fumarase deficiency in HS_121 (red) rela-
tive to control (black) PGL/PCC samples.
(C) Loss of fumarase activity is associated with a higher fumarate concentra-
tion in tumor HS_121 than that in control PGL/PCC (n = 6). For controls, data
are mean ± SEM. See also Table S10.
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Identified in Colorectal Cancer and Glioblastoma
We investigated whether the hypermethylator phenotype identi-
fied in PGL/PCC showed similarities with previously described
CIMP phenotypes. We analyzed publicly available data concern-
ing colorectal cancers (Hinoue et al., 2012) and glioblastomas
(Noushmehr et al., 2010), obtained with the same Illumina Infin-
ium HM27 methylation array used in this study. For each CpG
site, we calculated the mean beta value difference between
tumors with and without a hypermethylator phenotype (CIMP-
high in colorectal cancer, G-CIMP in glioblastoma). Although
we found a significant overlap between hypermethylated loci in
the three cancers, the patterns of hypermethylation were partic-
ularly similar between PGL/PCC and G-CIMP glioblastomas
(Figure 7A). Of 2,241 CpG sites hypermethylated in PGL/PCC
of the M1 subgroup (mean beta value difference >0.2 as
compared to non-M1 tumors), 847 (38%) were also hypermethy-
lated in G-CIMP glioblastomas, whereas only 279 (12%) were
hypermethylated in CIMP-high-colorectal tumors (Figure 7B).
Gene set enrichment analysis (GSEA) confirmed that the set
of genes hypermethylated in PGL/PCC was more significantlyenriched in genes hypermethylated in G-CIMP glioblastomas
(enrichment score = 0.75) than genes hypermethylated in
CIMP-high-colorectal cancers (enrichment score = 0.47) (Fig-
ure S5). Seventeen of the 191 genes epigenetically silenced in
PGL/PCC were significantly hypermethylated and downregu-
lated in glioblastoma (including PNMT and RBP1); 21 were
hypermethylated but without significant downregulation (like
KRT19); and 119, like NPY, were not found to be hypermethy-
lated in glioblastoma (Table S8). The similarity between PGL/
PCC and glioblastoma hypermethylator phenotypes may reflect
the preferential activities of the 2-OG-dependent demethylases
inhibited in these two cancers.
DISCUSSION
Metabolic reprogramming in cancer has long been regarded as
an indirect response to cell proliferation, but recent evidence
has shown that metabolites themselves can be oncogenic by
altering several cellular processes (Ward and Thompson,
2012). The oncometabolite 2-HG, produced by mutated IDH
enzymes, establishes the G-CIMP phenotype in glioma by inhib-
iting DNA and histone demethylases (Xu et al., 2011). Succinate
and fumarate can activate the oncogenic HIF pathway by inhib-
iting HIF prolyl-hydroxylases (Brie`re et al., 2005; Selak et al.,
2005). Here, we demonstrate that succinate accumulation in
SDH-deficient PGL/PCC establishes a hypermethylator pheno-
type, by inhibiting 2-OG-dependent oxidative demethylation.
Besides, we describe a specific model of SDH-related PGL/
PCC, generated by knocking out Sdhb gene in chromaffin cells.
In the past, the lack of an appropriate cellular model has
opposed severe limitations to the understanding of SDH-related
oncogenesis. Ourmodel displays a complete inactivation of SDH
activity, which cannot be achieved by siRNA-mediated gene
silencing, and will be a crucial tool for deciphering the conse-
quences of SDH inactivation in these cells. Our study also led
to the identification of a case of FH germline mutation in an
apparently sporadic PCC displaying a hypermethylator pheno-
type. FH mutations are known to predispose to hereditary leio-
myomatosis and renal cell cancer (Tomlinson et al., 2002) but
have never been described in PGL/PCC. Altogether, these find-
ings shed light on a novel pathway explaining the tumor-sup-
pressive role of SDH and FH and, echoing the role of IDH
mutation in glioma, emphasize the link between TCA cycle
dysfunction and epigenomic alterations in cancer. Gastrointes-
tinal stromal tumors, renal cancer, and leiomyomas harboring
SDH or FH mutations may also display epigenetic reprogram-
ming, which should be assessed in future DNA methylation
studies.
Many cancer-specific hypermethylation events occur in pro-
moter regions of genes that are not normally expressed and
are therefore not affected by DNAmethylation changes (Widsch-
wendter et al., 2007). To distinguish DNA methylation events of
potential functional significance (‘‘driver events’’) from these
‘‘passenger events’’, we integrated the DNA methylation data
with gene expression profiles of the same tumors. Only 11.5%
of genes with significant promoter hypermethylation in PGL/
PCC of the M1 subgroup were underexpressed in these tumors.
This is consistent with previous reports in colorectal cancer
(7.3%; Hinoue et al., 2012) and glioblastoma (17%; NoushmehrCancer Cell 23, 739–752, June 10, 2013 ª2013 Elsevier Inc. 747
Figure 6. The Hypermethylator Phenotype Is Particularly Severe in SDHB-Mutated Tumors
(A) Mean methylation of all CpG island probes significantly hypermethylated in M1 tumors, according to tumor subgroup. Box-and-whisker plots show the
distribution of mean beta values relative to each DNA methylation subgroup. M1 tumors are separated into SDHB-mutated and SDHB-wild-type tumors. The
middle bar, median; box, interquartile range; bars extend to 1.5 times the interquartile range.
(B) Mean expression of genes significantly hypermethylated and downregulated in M1 tumors, according to tumor subgroup.
(C) Distribution of mean expression levels of target genes relative to the mean methylation levels of CpG sites hypermethylated in M1 tumors. Tumor subgroups
are represented with a color code, and the mutations of non-SDHB-mutated M1 tumors are indicated next to each dot.
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Hypermethylator Phenotype in SDH-Related PGL/PCCet al., 2010). Thus,most hypermethylated CpG sites appear to be
silent consequences of the inhibition of DNA demethylases, with
no evident functional impact. We were however able to show an
overall correlation between the level of hypermethylation and
downregulation of gene expression. In particular, we identified
191 genes that showed significant hypermethylation and down-
regulation in M1 tumors and whose expression was closely
correlated with the degree of DNA methylation.
Two of the genes showing the strongest evidence for epige-
netic silencing in hypermethylated PGL/PCC are, respectively,
involved in the differentiation of chromaffin cells (PNMT;
Eisenhofer et al., 2011) and the epithelial-to-mesenchymal tran-
sition (KRT19; Moreno-Bueno et al., 2006), which was recently
identified as the first mechanistic clue to explain the particularly
invasive phenotype of SDHB-related tumors (Loriot et al., 2012).
The PNMT gene encodes the phenyl-ethanolamine-N-methyl-
transferase, a key enzyme of chromaffin cell metabolism, which
catalyzes the conversion of noradrenaline to adrenaline.
Reduced PNMT expression has been reported in SDH-related
tumors, leading to an immature catecholamine secretory profile
with predominant secretion of noradrenaline or dopamine (Burni-
chon et al., 2012b; Eisenhofer et al., 2001). Our findings reveal
that PNMT is hypermethylated in SDH-related tumors, together
with four other genes implicated in catecholamine metabolism
(DRD2, SULT1A1, SLC6A2, and NPY). Epigenetic regulation is
thus a previously unsuspected mechanism explaining the dedif-
ferentiated phenotype of this subgroup of PGL/PCC. Another
target of the PGL/PCC hypermethylator phenotype, RBP1, is
also epigenetically silenced in G-CIMP gliomas (Noushmehr
et al., 2010) and several cancer cell lines and primary tumors
(Esteller et al., 2002). RBP1 is involved in retinoic acid signaling,
leading to loss of cell differentiation and tumor progression
(Farias et al., 2005) and may thus have a tumor-suppressive
role in PGL/PCC. Studies aimed at elucidating the functional
consequences of epigenetic gene silencing will undoubtedly
improve our understanding of the role of DNA hypermethylation
in PGL/PCC tumorigenesis.748 Cancer Cell 23, 739–752, June 10, 2013 ª2013 Elsevier Inc.SDH- and VHL-related tumors were previously shown to have
similar gene expression features, like the activation of hypoxia-
related genes (Dahia et al., 2005). In the COMETE cohort, we
showed that, although close, these tumors were classified in
two separate gene expression clusters (C1A and C1B) (Burni-
chon et al., 2011). Here, we found that 150 out of 344 genes
(44%) significantly downregulated in SDH- as compared to
VHL-tumors were hypermethylated (data not shown). Epigenetic
remodeling thus explains a significant part of transcriptional
differences between SDH- and VHL-related tumors.
SDHB mutations confer a much worse prognosis than muta-
tions in other SDHx genes (Amar et al., 2007). No mechanism
has been proposed to explain these differences. We found
that although all SDHx-mutated tumors displayed a hyper-
methylator phenotype, the level of hypermethylation was
significantly higher, and the expression of target genes was
significantly lower in SDHB-mutated tumors. As target genes
include genes implicated in neuroendocrine differentiation and
epithelial-to-mesenchymal transition (EMT), this may explain
the particular malignancy of SDHB-mutated tumors. SDHB
encodes a catalytic subunit of SDH (Rutter et al., 2010). We
hypothesize that SDH inactivation may be more complete in
SDHB-mutated tumors than in tumors harboring mutations in
other subunits, leading to a higher succinate accumulation
and hence to a stronger inhibition of 2-OG-dependent demethy-
lation. However, we were not able to detect significant differ-
ences in succinate concentrations between SDHB-mutated
and other SDH-related tumors. Future studies will be needed
to dissect the functional impact of mutations affecting different
SDH subunits.
There have recently been several promising findings for epige-
netic cancer therapy. Notably, Tsai et al. (2012) demonstrated
that low doses of the DNA demethylating agents, DAC and
azacitidine, had durable antitumor effects on hematological and
epithelial tumor cells. Thus, low doses may help avoid the
extreme toxicities of these agents at high dose that have pre-
vented the investigation of the true clinical responses. We show
Figure 7. Comparison of Hypermethylator
Phenotypes in PGL/PCC, Colorectal
Cancer, and Glioblastoma
(A) Correlation between CIMP-specific hyper-
methylation patterns in the three cancers. The
mean beta value difference between CIMP and
non-CIMP tumors was calculated for all CpG sites
in each cancer type. Each scatterplot represents
the correlation of beta value differences between
two cancers. Red dots indicate CpG sites hyper-
methylated in the CIMP subgroups of both can-
cers (beta value difference >0.2 between CIMP
and non-CIMP tumors).
(B) Venn diagram showing hypermethylated loci
shared by the PGL/PCC hypermethylator pheno-
type, the colorectal cancer CIMP-high phenotype,
and the glioblastoma G-CIMP phenotype. See
also Figure S5.
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Hypermethylator Phenotype in SDH-Related PGL/PCCthat the increasedmigratory capacities ofSdhb/mouse chro-
maffin cells are repressed by transient DAC treatment, even at a
10 nMconcentration, which led tominor cytotoxicity. The precise
molecular changes associated with these treatments will have to
be deciphered in future studies, both in vitro and in vivo. In viewof
these findings, the reversal of promoter DNA hypermethylation
and associated gene silencing may rise as an attractive alterna-
tive approach to surgery for SDHx- and FH-mutated PGL/PCC.
NPY, which shows the strongest transcriptional silencing in
M1 tumors, may be a good marker. NPY levels were shown to
be increased in the plasma and tumors of patients with
PCC and to be significantly lower in extra-adrenal tumors (deS
Senanayake et al., 1995). A comprehensive study of candidate
markers in a large independent cohort will be useful to determine
the best marker of this aggressive subgroup.
In summary, our analysis indicates that PGL/PCC can be clas-
sified into three distinct subgroups according to genome-scale
DNA methylation changes. The identification of a hypermethyla-
tor phenotype in SDHx- and FH-mutated tumors helps in
explaining both the tumor-suppressive role of these genes and
some of the phenotypic characteristics of these tumors. The
malignancy of SDHB-mutated PGL/PCCmay be due to a severe
epigenetic silencing of genes involved in cell differentiation and
EMT. These findings have clinical implications for PGL/PCC
diagnosis and may lead to targeted epigenetic treatment for
patients with TCA cycle alterations.
EXPERIMENTAL PROCEDURES
Collection and Processing of PGL/PCC and Normal Tissue Samples
A total of 145 tumor samples from 145 different patients recruited in
the COMETE network from 1993 to 2008 were included in the study. Ethical
approval for the study was obtained from the institutional review boardCancer Cell 23, 739–7(CPP Paris-Cochin, January 2007). All patients
provided written informed consent for the
collection of samples and subsequent analyzes.
Three adrenal medulla samples from healthy
individuals were also included as controls. Germ-
line DNA was extracted from leukocytes using
standard protocols. Tumor and normal medulla
samples were powdered in liquid nitrogen
(30–50 mg), and DNA was extracted using aQIAamp DNA Mini Kit or an AllPrep Kit (QIAGEN, Hilden, Germany). For
details, see the Supplemental Experimental Procedures.
DNA Methylation Arrays
Whole-genome DNA methylation was analyzed in 145 PGL or PCC and three
normal adrenal medulla samples using the Illumina Infinium HumanMethyla-
tion27 assay (Bibikova et al., 2009). Twenty-four samples were later reana-
lyzed using the more comprehensive Illumina Infinium HumanMethylation450
Beadchips. Microarray experiments were performed by Integragen SA (Evry,
France). In brief, genomic DNA was bisulfite-converted using the EZ-96 DNA
Methylation Kit (Zymo Research, Irvine, CA, USA), whole-genome amplified,
enzymatically fragmented, and hybridized to the BeadChip arrays in accor-
dance with the manufacturer’s instructions. The beta value DNA methylation
scores for each locus were extracted together with detection p values from
Illumina GenomeStudio software. As described elsewhere (Hinoue et al.,
2012), we replaced data points with a detection p value >0.05 by ‘‘NA’’ values,
and we masked data points as ‘‘NA’’ for 4,484 probes that contain single-
nucleotide polymorphisms or overlap with a repetitive element that are not
uniquely aligned to the human genome (NCBI build 36/Hg18) or that overlap
with regions of insertions and deletions in the human genome. Probes were
considered to be in a promoter CpG island if they were located within a
CpG island (UCSC database) and less than 1,500 bp away from a transcrip-
tion start site.
DNA Methylation-Based Classification of Pheochromocytomas
and Paragangliomas
We used consensus clustering (Monti et al., 2003) to identify PGL/PCC sub-
groups on the basis of their DNA methylation profiles. We selected the 10%
most variant probes (n = 2,152) among those that did not contain any «NA»-
masked data point. We then established consensus partitions of the data
set in K clusters (for K = 2, 3, ., 8), based on 1,000 resampling iterations of
hierarchical clustering, with Pearson’s dissimilarity as the distance metric
and Ward’s method for linkage analysis. We used the cumulative distribution
functions (CDF) of the consensus matrices to determine the optimal number
of clusters, considering both the shape of the functions and the area under
the CDF curves (Figure S1). The Bioconductor ConsensusClusterPlus pack-
age was used for consensus clustering analysis.52, June 10, 2013 ª2013 Elsevier Inc. 749
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Chromaffin Cells
RRBS was performed by Integragen SA (Evry, France), as described else-
where (Gu et al., 2011; Smallwood and Kelsey, 2012). In brief, 300 ng of
mouse genomic DNA were digested with 14 units of MspI (NEB). After
end-repair, A-tailing, and ligation to methylated Illumina adapters, the library
fragments of 40–220 bp were gel isolated, subjected to a double bisulfite
conversion with the EpiTect Bisulfite kit from QIAGEN, PCR amplified, and
sequenced on an Illumina HiSeq2000 sequencer as paired-end 75 bp reads.
We used Trim Galore! (http://www.bioinformatics.babraham.ac.uk/projects/
trim_galore) to filter out the adaptor sequences. Bisulfite mapping and
methylation calling were performed in a single step using the bismark soft-
ware (Krueger and Andrews, 2011). Only reads uniquely aligned to the
mm9 assembly of the mouse genome were retained, and we required a
coverage of at least ten reads to call methylation score for a CpG site. We
downloaded the list of Mouse CpG islands from the UCSC genome browser,
and we inferred a DNA methylation rate to each CpG island with more than
ten individual CpG measurements and more than 100 total reads. To identify
differentially methylated CpG sites or CpG islands, we compared the number
of methylated and unmethylated observations in WT and Sdhb/ cells
using Fisher’s exact test. CpG islands with an FDR-adjusted p value <0.05
and absolute methylation difference >5% were considered differentially
methylated. Human and mouse orthologs were downloaded from the Mouse
Genome Database (Eppig et al., 2012).
Generation of Sdhb–/– Immortalized Mouse Chromaffin Cells
Sdhb-floxed mice were generated at the Mouse Clinical Institute (Illkrich,
France). A targeting vector containing Sdhb exon 2 flanked by LoxP sites
followed by a neomycin (neo) selection cassette flanked by Frt sites (Fig-
ure 2A) was introduced into P1 (129 S2/SvPas) ES cells by electroporation.
Two positive embryonic stem clones were injected into C57BL/6J blasto-
cysts, and the resulting male chimeras gave germline transmission. These
mice were mated to Flipase-expressing mice to delete the Neo cassette.
Sdhb+/lox mice were intercrossed to obtain Sdhblox/lox mice, and mouse
chromaffin cells (mCCs) were isolated from the adrenal medulla of these
Sdhblox/lox as described elsewhere (Kolski-Andreaco et al., 2007). All studies
were performed in accordance with the relevant guidelines of the French
Ministry of Agriculture (Authorization Executive Order A751532) for scientific
experimentation on animals, European Communities Council Directive, and
international ethical standards. Cells were cultured at 37C, under 5% CO2
in a standard medium containing Dulbecco’s modified Eagle’s medium
with glutamine and a high glucose concentration (DMEM glutaMAX, GIBCO,
Life Technologies, Saint Aubin, France) supplemented with 10% fetal bovine
serum (GIBCO) and 1% penicillin-streptomycin (GIBCO). The cultures
remained quiescent for 6 months, after which some started to grow sponta-
neously from mCCs clusters. These immortalized cells were isolated
and infected with 107 plaque-forming units (pfu)/ml of an adenovirus
expressing Cre-recombinase (Ad5CMV-Cre, Cell BioLabs, San Diego). A
clonal approach by limiting dilution cloning assay was used to obtain homog-
enous Sdhb immortalized mCCs clones (imCC clones 6 and 8). Sdhb/
and Sdhblox/lox (referred to as WT) imCCs were maintained in standard
medium with or without 2.5 mM dimethyl 2-oxoglutarate (Sigma-Aldrich,
St. Louis).
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Methylation array data from the 148 human samples and RRBS
data from the four mouse cell lines analyzed in this study have been
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gov/geo) and are accessible through the GEO series accession number
GSE43298.
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